National microbiological surveillance of the susceptibility of gonococcal isolates to antimicrobial agents

JO-ANNE R DILLON T HE INCIDENCE OF GONORRHEA HAS BEEN DECLINING IN
Canada and other industrialized countries: in 1981. 56.330 cases of gonorrhea were reported in Canada compared with 13,822 cases in 1990 (l). The reasons for this decline are unknown: however. educational programs for U1e primary prevention of acqu ired immune deficiency syndrome as well as effective therapy may have played a role. Persons aged 15 to 29 years accounted for more than 75% of a ll reported cases of gonon·hea with twice as many female cases in the ·under 20' age group. Females with gonorrhea are at increased risk for serious complications. such as pelvic inflammatory disease (P!D) which. in turn. may lead to sequelae such as infertility and ectopic pregnancy. Untreated or ineffectively treated gonococcal infections are a significant cause of PID .
Despite U1e decrease in the number of cases of gonorrhea. the prevalence of isolates resistant to antimicrobial agents used for treatment has steadily increased in Canada. This res istance is caused by eiU1 er chromosomal mutations or plasmids conferring antibiotic resistance. A number of ch romosomal loci which produce phenotypes wiU1 reduced susceptibili ty to antimicrobia l agents have been described (2) . Some chromosomal mutations are characterized by s imultaneous resistance to other unrelated antimicrob ia l agents and some act in concert to produce step-wise. additive increases in resistance. Decreased antimicrobial susceptibility in gonococci caused by chromosomal 202 mutation (as well as plasmid-mediated mechanisms) leads to increased frequencies of treatment fai lure . requiring ilie periodic revision of treatment guidelines wh ic h reflect the specific antimicrobial s u sceptibilities of a country or region. Chromosomal resistance is defined as a minimum inhibitory concentration (M IC) of at least 2 mg/L for pen icillin. tetracycline and erythromycin and an MIC of at least 128 mg/L for spectinomycin (3). Breakpoints have not been establis hed for antimicrobials such as ceftriaxone. For quinolone antibiotics such as ciprofloxacin . an MIC of 0 .25 to 0.5 mg/L has been considered resistant (4) . In Canada. alU1ough plasmid-mediated resistance to either penicillin or tetracycline has replaced chromosomal resistance as the major mechanism of resistance in many regions. the development of chromosomal resistance remains an important potential cause of treatment failure. particu larly to newer antimicrobials such as the qu inolones. cefixime and ceftriaxone. For example. the 1988-89 national antimicrobial susceptibility surveillance study undertaken by our laboratory indicated that 1.4% of 3031 gonococcal isolates were chromosomally resistant to penicill in and 2.6% were resistant to tetracycline . Isolates with chromosomally-medi ated penicillin resistance were a lso resistant to one to iliree unrelated an tibiotics such as tetracycline. eryti1romycin and ce foxitin. The total burden of chromosomal resistance observed in U1e study. inclu ding all combinations of a ntibiotic res istance tested and resistance to erythromycin. was 15.5% of U1e isolates .
In many areas of Canada. U1e most clinically important mechanism of resistance is plasmid-mediated resistance to either penicillin or tetracycline. The first penicillinase-producing isolates of Neisseria gonorrhoeae (PPNG) in Canada were isolated in 1976 (2).
PPNG strains carry one of a family of related plasmids U1at produce the TEM-1 type, beta-lactamase. In addition to carrying an enzyme that destroys penicillin. PPNG iso lates may also exhib it chromosomal resistance to antibiotics such as tetracycline and. in rare instances . spectinomycin or quinolone antimicrobials . The production of a beta-lactamase is indicative of a PPNG isolate: U1ese strains generally have MICs greater than 16 mg/L; however. in rare cases. isolates with lower MICs may produce beat-lactamase. All beta-lactamase-producing gonococci. irrespective of MICs. are considered to be clinically resistant to penicillins.
In 1986, the first N gonorrhoeae isolates from Canada with plasmid-mediated resistance to tetracycline (TRNG) were reported in B1itish Columbia (5) . TRNG isolates acquired the tetM detem1inant wiU1in the gonococcal conjugative plasmid (6) . TRNG isolates are presumptively identified based on their antimicrobial susceptibility to tetracycline; isolates with an MlC of 2 to 8 mg/L are considered to be chromosomally resistant and isolates wiU1 an MIC of at least 16 mg/L are considered to carry plasmid-mediated resistance to tetracycline (3). Plasmid-mediated resistance is identified only definitely through the use of tetM-specific diagnostics such as DNA probing or gene amplification strategies such as the polymerase chain reaction.
Because of the clinical importance of antibiotic resistant gonococci, the National Laboratmy for Sexually Transmitted Diseases (NLSTD) has undertaken national collaborations with provincial public health laboratories and other centres to determine the prevalence of antibiotic resistance in gonococcal isolates from Canadian centres. Since the isolation of the first PPNG isolate in 1976. we have requested that all gonococcal isolates with either plasmid-mediated or chromosomal resistance to antimicrobial agents be sent to U1e NLSTD for national documentation . confirmation of and extension of antimicrobial susceptibili ty profiles and strain typing (plasmid content analysis: auxotype. ie. nutritional requirement determination : and serotyping witi1 a panel of monoclonal antibodies). In addition. periodic retrospective (1973 -74. 1978-79) or prospective (1988-89. 1991-92) national collaborative studies have been undertaken to determine the antim icrobial susceptibility of gonococcal isolates from across Canada which do not carry plasmid-mediated resistance. to evaluate temporal and geographic changes in susceptibil ity and Lo determine the molecular epidemiology of gonococcal isolates across Canada. In turn. U1e data are used to develop national recommendations for ilie txeatment of gonorrhea as well as to develop models of gonococcal strain transmission iliat may impact on epidemiological practices. For example. from March 1. 1988 to March 31. 1989 we conducted a national collaborative study to detem1ine ilie clinical and biological factors influencing gonococcal infections and treatment in children and adults in Canada. This was the first study in Canada in which consecutive isolates of N gonorrhoeae were prospectively collected fro m 26 participating centres across Canada: 19% of all reported cases of gonorrhea were tested. Notable results of ilie study included U1e first national data on the prevalence of iso lates wiU1 chromosomal resistance, and documentation of reduced susceptibility of isolates to certain antimicrobial agents (eg. the MICgos of isolates to spectinomycin doubled since 1978 from 8 to 16 mg/L and the M!Cs of isolates to ceftriaxone exhibited a biphasic disUibution wiU1 ilie less susceptible iso lates correlating with resistant strain types). In addition . significant geographic differences in susceptibility and strain types were documented. with isolates from U1e Atlantic provinces and some areas of the Nortlwvest Territories being more susceptible to penicillin and tetracycline U1an isolates from otl1er regions of Canada. Comparison of these data with previous national studies indicated that the susceptibility to penicillin of isolates which do not carry plasmid-mediated resistance to penicillin or tetracycline deCI·eased from 45% of 732 gonococcal isolates in 1973 to 19.2% of 608 isolates in 1991. These shifts in antimicrobial susceptibility have also been reflected in shifts in the predominant strain type as determined by auxo/serotyping metl1ods.
Gonococcal isolates which inactivate penicillin PPNG represented 9.6% of all reported cases of gonorrhea in 1990 compared with 5% in 1985. The distribution of PPNG in Canada has shifted from a sporadic distribution across ilie counUy to clustering in urban areas. for example Metro Toronto. ln 1991. 64.8% (827 of 1277 isolates) of all PPNG submitted to the NLSTD were recovered from the Metro To ron to area. ln 1988. 1. 7% (10 of 591) of PPNG isolates also canied plasmidmediated resistance to teu·acycline (PP/TRNG): by 1991. U1e number of PP/TRNG increased to 568 isolates wiU1 74% of U1ese isolates from U1e Toronto area. The number of gonococcal isolates wiili plasmidmediated resistance to tetracycline has also increased from six isolates in 1986 to 890 isolates in 1991. While U1e incidence of TRNG is still under 1% of reported cases of gonococci. U1eir steady increase in prevalence is reminiscent of U1e steady increase of PPNG isolates over a decade ago.
Because U1e prevalence of resistant isolates changes temporally and geographically. the efficacy of antimicrobials used clinically must be monitored continually. For U1is reason U1e national antimicrobia l susceptibility monitoring study of 1988-89 has been re-initiated and the network of collaborating centres has been expanded . The sample of gonococci collected is proportional to the number of gonococci reported from a given area. In addition. U1e NLSTD will continue to collect and type all PPNG and TRNG isolated in Canada. In order to encourage local laboratories to monitor the susceptibility of ilie gonococcal isolates in U1eir regions. a national antimicrobial susceptibility quality control program has been initiated wiU1 eight centres participating. In the program, standard methods for testing the antimicrobial susceptibility of N gonorrhoeae isolates have been implemented following the methods recommended by the National Committee for Clinical Laboratory Standards (3) . The NLSTD provides quality assurance for specific lots of GC agar base. providing these and reference strains to participants. In addition to the microbiological studies. the NLSTD is collaborating '.vith the Division of STD Control. Bureau of Communicable Disease Epidemiology. to collect retrospective case history data for data linkage. Findings regarding significant national trends are communicated to various groups and study participants as well as to appropriate authmities on an on-going. timely basis. Study centres are encouraged to publish data from their regions and forums are provided for discussing the impact of regional and national trends as well as to review and develop national recommendations for the treatment of gonorrhea.
The impact of the 1988-89 study. together witl1 on-going surveillance of antibiotic-resistant gonococci. was underlined in March 1991 when a national working group convened in Ottawa to review national guidelines for the diagnosis and treatment of STDs. At that time, significant changes to the recommended treatments for gonorrhea were made. Because of the high overall prevalence of isolates resistant to penicillin/ampicillin and tetracycline, these agents could no longer be recommended for the treatment of uncomplicated gonococcal infections (either singly or in combination) unless active monitoring for resistance to penicillin was undertaken. if the percentage of penicillin-resistant isolates was under 3% and if the infection was acquired in the same geographic area. Ceftriaxone (250 mg intramuscular in a single dose) was recommended as the preferred therapy for treatment of uncomplicated gonococcal in-204 fections in adolescents and adults (7) . Several oral regimens were also recommended: cefixime (800 mg in a single dose). ciprofloxacin (500 mg in a single dose) and ofloxacin (400 mg orally in a single dose). Spectinomycin (2 gm intramuscular in a single dose) continues to be an effective alternative therapy. Because the risk of having sin1Ultaneous chlamydia infections is high , treatment. for gonococcal infections must be accompanied by treatment for chlamydia! infections (ie. doxycycline/tetracycline). Information regarding treatment. of other gonococcal infections or for treating gonococcal infections in children can be obtained from the Canadian guidelines for t11e prevention, diagnosis, management and treatment of STDs in neonates, children. adolescents and adults (7) .
